ABSTRACT
ABCB1 and ABCG2 are the important ATP-binding cassette (ABC) transporters associated with multidrug resistance (MDR). Herein, we designed a series of imidazo[1,2-a]pyridine derivatives as dual-target inhibitors of ABCB1 and ABCG2 through the scaffold hopping strategy. Compound Y22 displayed potential efflux function inhibitory toward both ABCB1 and ABCG2 (reversal fold: ABCB1 = 8.35 and ABCG2 = 2.71) without obvious cytotoxicity. Y22 also enhanced the potency of antiproliferative drugs in vitro. Mechanistic studies demonstrated that Y22 slightly suppressed ATPase activity but did not affect the protein expression of ABCB1 or ABCG2. Notably, Y22 exhibited negligible CYP3A4 inhibition and enhanced the antiproliferative activity of adriamycin in vivo by restoring the sensitivity of resistant cells. Thus, Y22 may be effective clinically in combination with common chemotherapy agents. In summary, Y22 is a potential dual-target inhibitor that reverses MDR by blocking the efflux function of ABCB1 and ABCG2.
Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 2 , Antineoplastic Agents , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Neoplasm Proteins , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Drug Resistance, Multiple/drug effects , Drug Resistance, Neoplasm/drug effects , Pyridines/pharmacology , ATP Binding Cassette Transporter, Subfamily B, Member 2/antagonists & inhibitors , Neoplasm Proteins/antagonists & inhibitors , HumansABSTRACT
When exposed to electrophiles, human colorectal cancer cells (HCT116) counteract oxidative stress through activating NF-E2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway. To identify new activators, luciferase reporter gene assay was used to screen in-house database of our laboratory, leading to a novel α-pyrone compound 1 as a hit. 2 with 2-fluoro phenyl group exhibited the strongest ARE inductive activity in the first round structure-activity relationship (SAR) study. Biological studies showed the compound induced nuclear translocation of Nrf2 preceded by phosphorylation of ERK1/2. The data encouraged us to use 2 as lead and 20 derivatives were synthesized to discuss a more detailed SAR, leading to a more potent compound 9, which can be the starting compound for further modification.
Subject(s)
Antioxidants/metabolism , NF-E2-Related Factor 2/metabolism , Pyrones/chemical synthesis , Pyrones/pharmacology , Response Elements/drug effects , Chemistry Techniques, Synthetic , HCT116 Cells , Humans , Inhibitory Concentration 50 , Pyrones/chemistry , Structure-Activity RelationshipABSTRACT
IκB kinase ß (IKKß), an attractive anti-inflammation and anti-cancer target, plays a crucial role in the activation of NF-κB signalling pathway. To identify novel IKKß inhibitors, we combined structure-based and ligand-based methods based on the co-crystal structure of IKKß. According to the chemical similarity, 162 reported IKKß inhibitors were divided into five classes. For each class, a 3D pharmacophore model was established based on the binding conformations of the compounds. The validated models were further used in virtual screening. Twelve drugable compounds were retained for biological test, resulting in two novel inhibitors with IC50 values lower than 10 µM. Compared to other models, our method considers the crystal structure of IKKß for the first time.
Subject(s)
I-kappa B Kinase/chemistry , Molecular Conformation , Protein Kinase Inhibitors/chemistry , Protein Structure, Tertiary , Crystallography, X-Ray , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/methods , Humans , I-kappa B Kinase/antagonists & inhibitors , I-kappa B Kinase/metabolism , Ligands , Models, Molecular , Molecular Structure , Protein Binding , Protein Kinase Inhibitors/metabolism , Protein Kinase Inhibitors/pharmacology , Structure-Activity RelationshipABSTRACT
Overexpression of ABCB1 is one of major barriers for multidrug resistance in chemotherapy and limits drug oral bioavailability. Inhibition of ABCB1 would sensitize multidrug resistance in clinical cancer chemotherapy. With this aim, a 3D pharmacophore model was created based on known ABCB1 inhibitors with correlation coefficient of 0.94, comprising three hydrophobic features and one hydrogen bond acceptor. It was further validated and used to search our in-house 3D database for potential ABCB1 inhibitors. The inhibitory activities of the best hits were evaluated by several biological assays, such as rhodamine 123 accumulation assay, chemosensitization assay, multidrug resistance 1-Madin-Darby canine kidney cells/Madin-Darby canine kidney cells permeability assay. Finally, compounds YZ-3 and YZ-16 were identified as potential leads to be developed in the designing of novel potent ABCB1 inhibitors.
Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors , Aminoquinolines/chemistry , Benzothiazoles/chemistry , Drug Design , Heterocyclic Compounds, 3-Ring/chemistry , ATP Binding Cassette Transporter, Subfamily B , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Aminoquinolines/metabolism , Aminoquinolines/toxicity , Animals , Benzothiazoles/metabolism , Benzothiazoles/toxicity , Cell Survival/drug effects , Databases, Factual , Dogs , Drug Evaluation, Preclinical , Drug Resistance, Neoplasm/drug effects , Heterocyclic Compounds, 3-Ring/metabolism , Heterocyclic Compounds, 3-Ring/toxicity , Humans , Hydrophobic and Hydrophilic Interactions , K562 Cells , Madin Darby Canine Kidney Cells , Models, Chemical , Permeability/drug effects , Quantitative Structure-Activity Relationship , Quinolones/chemistry , Quinolones/metabolism , Quinolones/toxicity , Rhodamine 123/chemistry , Rhodamine 123/metabolismABSTRACT
IκB kinase ß (IKKß) is an important anti-cancer target that plays crucial role in activating the transcription factor NF-κB in response to various inflammatory stimuli. In order to discover novel IKKß inhibitors, a 3D chemical-feature-based QSAR pharmacophore model was established. A homology model of IKKß enzyme was also developed to study the binding mode of IKKß and its inhibitors. The two models were consistent in predicting the binding conformation of IKKß inhibitor. Based on the virtual screening using the pharmacophore model, 16 compounds from SPECS database were selected after multiple filtrations for biological test. Two compounds with IC(50) values lower than 10 µM were discovered.
